Shanghai Vitalgen BioPharma Co., Ltd.
13
4
8
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 13 trials
8%
1 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R08b in Parkinson's Disease Patients With GBA1 Mutations
Role: lead
A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R09b in Severe AADC Deficiency
Role: lead
A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R09b in Patients With Parkinson's Disease
Role: lead
VGN-Ex05e in Patients With Autism Spectrum Disorder Associated With Severe Self-Injurious and Aggressive Behaviors
Role: collaborator
Safety and Tolerability of VGR-R01 for Patients With Bietti Crystalline Dystrophy
Role: lead
Study to Evaluate the Efficacy and Safety of VGR-R01 Gene Therapy in Patients With Bietti Crystalline Dystrophy
Role: lead
The Safety and Efficacy of VGO-Cs01p in Patients With CD7-positive Relapsed/Refractory Acute T-lymphoblastic Leukemia
Role: collaborator
A Study to Evaluate the Tolerability, Safety and Efficacy of VGM-R02b
Role: lead
An Exploratory Clinical Trial of VGN-R08b in Patients With Type II Gaucher Disease
Role: collaborator
Safety and Efficacy Evaluation of Autologous CRISPR-Cas12b Edited Hematopoietic Stem Cells
Role: collaborator
An Early Clinical Trial to Evaluate VGN-R09b for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency.
Role: collaborator
Lead-in Study of VGB-R04 Gene Therapy for Hemophilia B-- An Observational Survey Analysis Study
Role: lead
A Study to Evaluate the Safety and Efficacy of VGB-R04 in Adult Hemophilia B Patients
Role: lead
All 13 trials loaded